Theravance Biopharma, Inc. (TBPH) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is neutral: All seven analysts covering Theravance Biopharma rate it “Hold,” with an average 12-month price target of $19. Recent rating changes included Zacks downgrading the stock to Hold and Weiss modestly upgrading its Hold rating.
• Quarterly results missed expectations: The company reported a loss of $0.11 per share versus analysts’ expected earnings of $0.07, while revenue of $20.73 million also fell short of the $22.49 million estimate.
• A senior vice president sold 13,314 shares for about $226,700 under a pre-arranged trading plan and retained 213,476 shares. Institutional investors own 99.1% of the stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has earned a consensus rating of "Hold" from the seven analysts that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $19.00.

TBPH has been the topic of several research reports. BTIG Research dropped coverage on Theravance Biopharma in a research report on Thursday, September 24th. They issued a "neutral" rating on the stock. Weiss Ratings raised shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday, August 17th. Finally, Zacks Research lowered shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 7th.

Insider Activity

In related news, SVP Rhonda Farnum sold 13,314 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total transaction of $226,737.42. Following the completion of the sale, the senior vice president directly owned 213,476 shares in the company, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.65% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Globeflex Capital L P purchased a new stake in shares of Theravance Biopharma in the 1st quarter worth $171,000. Allspring Global Investments Holdings LLC bought a new stake in Theravance Biopharma during the first quarter valued at about $171,000. Financiere des Professionnels Fonds d investissement inc. bought a new stake in Theravance Biopharma during the first quarter valued at about $268,000. Squarepoint Ops LLC purchased a new stake in Theravance Biopharma in the second quarter worth about $302,000. Finally, Quantinno Capital Management LP increased its position in Theravance Biopharma by 32.9% in the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company's stock worth $293,000 after buying an additional 4,463 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $17.03 on Wednesday. The stock has a market capitalization of $884.18 million, a price-to-earnings ratio of 16.86 and a beta of 0.25. Theravance Biopharma has a 1-year low of $13.08 and a 1-year high of $21.03. The business's fifty day moving average price is $17.03 and its 200-day moving average price is $16.89.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). The firm had revenue of $20.73 million during the quarter, compared to the consensus estimate of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. Equities research analysts anticipate that Theravance Biopharma will post 1.56 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris. The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.